Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?

In June 2026, Helus Pharma reported that enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major ...
Yahoo Finance

Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact?

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...
Yahoo Finance

Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq

Cybin Inc., now operating as Helus Pharma, has rebranded and moved its U.S. listing from NYSE American to Nasdaq under the ticker HELP, following a previously filed US$100,000,000 at-the-market follow ...
Seeking Alpha

Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

Good morning, everyone, and thank you for taking the time today. I'm Mike Cola, CEO of Helus, and we're here today to discuss the results from our most recent Phase II signal finding study in ...
The Globe and Mail

Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety

The latest announcement is out from Cybin ( (HELP)). On March 5, 2026, Helus Pharma reported topline Phase 2 signal detection results for its investigational NSA HLP004 in adults with ...